CD8A and cancer: OVA encapsulated in pH‐responsive ZIF‐8 based nanoparticles (ZNPs) and Al3+ dopped ZNPs (ZANPs) can escape from lysosomes, release into the cytoplasm, and induce cross‐presentation eventually, which is essential for the initiation of CD8+ T‐cell responses for cancer immunotherapy.